Psoriatic Arthritis Treatment Market Is Projected to Expand At A CAGR Of 7.5% Between 2023 And 2031. The Arthritis Foundation defines psoriatic arthritis as an autoimmune inflammatory disease that primarily affects the skin. Majorly 30% of the patients suffering from psoriasis develop psoriatic arthritis during the later stages of the disease. Psoriatic arthritis affects men and women equally with a global prevalence rate of 6 per 100,000 people. It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans. The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and the recent development of interleukin-17 inhibitors. The occurrence is high in the Caucasian populations of North America and Europe followed by Asia Pacific.
According to the International Federation of Psoriasis Associations (IFPA) 2016 statistics, around 125 million people throughout the globe are suffering from psoriatic arthritis. The diagnosis of psoriatic arthritis is complex due to the presence of symptoms in patients such as tendinitis, inflammatory spinal pain, or dactylitis, which are most often misunderstood as arthritis. Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease such as mild, moderate, or severe psoriatic arthritis. The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab, and brodalumab have better drug safety and efficacy for the treatment of psoriatic arthritis. ABT-494 (Abbvie, Inc.) and Aprelimast (Celgene Corporation), and Certolizumab Pegol (UCB BIOSCIENCES GmbH) are being developed as targeted therapies and are set to launch during the forecast period from 2023 to 2030 and capitalize the psoriatic arthritis treatment market.
Key players identified for the psoriatic arthritis treatment market include:
Abbvie, Inc., Amgen, Inc., Bristol Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, F.Hoffman La-Roche AG, Janssen Global Services, Merck & Co., Novartis AG, Valeant Pharmaceuticals International, Inc. and Others.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Psoriatic Arthritis Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2022-2032 |
Base Year | 2023 |
Forecast Period | 2024-2032 |
Historical Year | 2022 |
Unit | USD Million |
Segmentation | |
Drug Class
| |
Route of Administration
| |
Distribution Channel
| |
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report